LONDON, England—A recently approved drug-eluting bioresorbable scaffold for the treatment of below-the-knee (BTK) chronic limb-threatening ischemia (CLTI) is highly likely to be cost-effective for ...

R3 Vascular announced today that a doctor treated the first patient in the ELITE-BTK pivotal trial of its drug-eluting bioresorbable scaffold. Dr. Brian DeRubertis of New York-Presbyterian and ...

The ARID II trial evaluates the Voro Urologic Scaffold for post-prostatectomy stress urinary incontinence, enrolling 266 patients across 30 US sites. The Voro Urologic Scaffold is designed to support ...

Research at Harvard has helped develop drugs that treat Parkinson's and Alzheimer's diseases, led to the development of nanofibers that protect first responders and service members, and ...

An expert touch was essential as JR Scaffold tackled a uniquely challenging project at Touch Water Treatment near Cambusbarron, Stirlingshire. The team installed intricate scaffolding around two pipe ...

Research Center for Green Materials and Advanced Processing, Yamagata University, 4-3-16, Jonan, Yonezawa 992-8510, Yamagata, Japan ...

The trial evaluates R3 Vascular's next generation drug eluting bioresorbable scaffold, MAGNITUDE®, for below-the-knee (BTK) PAD, which according to the American Heart Association affects more than 200 ...

The lawsuit said that the funding freeze would impact ongoing research that develops "novel drugs to fight Parkinson's and Alzheimer's diseases, engineer nanofibers to protect servicemembers and ...